Challenging the IDR Process of the No Surprises Act
In an exclusive video interview with Diagnostic Imaging, Josh Cooper, vice president of congressional affairs for the American College of Radiology (ACR), and Thomas Hoffman, vice president of legal for the ACR, discuss the ACR’s lawsuit over the IDR process of the No Surprises Act and the potential impact of the law on reimbursement and patient access to care.
The No Surprises Act, which went into effect on January 1, is intended to curtail surprise medical bills for patients who receive emergency care at out-of-network facilities and non-emergency care provided at in-network facilities. However, a key aspect of the law’s independent dispute resolution (IDR) process, as noted in the interim final rule for the legislation, has drawn legal challenges from medical organizations including the American College of Radiology (ACR).
According to the ACR, the IDR process, which providers can use to negotiate reimbursement amounts from insurers, was intended to consider several factors, including patient complexity, scope of services and qualified payment amount (QPA). However, the interim final rule for the legislation establishes the QPA, set by insurers, as the primary determining factor for the IDR process, notes the ACR. The ACR, along with the American College of Emergency Physicians and the American Society of Anesthesiologists, recently filed a lawsuit against the United States Department of Health and Human Services (HHS), challenging this provision of the IDR process of the No Surprises Act.
In a recent video interview, Thomas Hoffman, JD, CAE, vice president of legal for the American College of Radiology (ACR), and Josh Cooper, vice president of congressional affairs for the ACR, discussed the lawsuit and the potential impact of the current law’s IDR process upon reimbursement for radiologists and access to timely imaging for patients. Watch below.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
